title: [Medication treatment for Parkinson's disease].
abstract: In general, therapy for Parkinson's disease is dominated by dopamine agonists (DA) in younger patients and levodopa in older patients with comorbidities. Single or combined treatment with DA should be used as long as possible to avoid levodopa and associated complications. About 30% of our patients respond to DA monotherapy and tolerate it for quite a long time. It is important to sustain patient confidence. Although parkinsonism is an insidious disease of unknown cause resulting in destruction of important dopaminergic neurons, no other neurodegenerative disease can be treated as successfully.
authors.affiliation: Klinik und Poliklinik für Neurologie, Universitätsklinikum Carl Gustav Carus, Technische Universität Dresden. Heinz.Reichmann@uniklinikum-dresden.de
authors.forename: H
authors.initials: H
authors.lastname: Reichmann
mesh_terms: D000978:Antiparkinson Agents / Q000008:administration & dosage*; D015259:Dopamine Agents / Q000008:administration & dosage; D018491:Dopamine Agonists / Q000008:administration & dosage*; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007980:Levodopa / Q000008:administration & dosage*; D010300:Parkinson Disease / Q000188:drug therapy*; D017410:Practice Guidelines as Topic; D010818:Practice Patterns, Physicians'; D016896:Treatment Outcome
chemical_list: D000978:Antiparkinson Agents; D015259:Dopamine Agents; D018491:Dopamine Agonists; D007980:Levodopa